8 studies found for:    BT-062
Show Display Options
Rank Status Study
1 Recruiting BT062 in Combination With Lenalidomide/Dexamethasone in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: BT062 , intravenous administration
Phases: Phase 1 / Phase 2
Sponsor/Collaborators: Biotest Pharmaceuticals Corporation;   Biotest
Study Start: July 2012
Primary Completion: July 2014
2 Active, not recruiting Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: BT062
Phases: Phase 1 / Phase 2
Sponsor/Collaborators: Biotest Pharmaceuticals Corporation;   Biotest
Study Start: August 2010
Primary Completion: July 2013
3 Completed Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: BT062
Phase: Phase 1
Sponsor/Collaborators: Biotest Pharmaceuticals Corporation;   Biotest
Study Start: August 2008
Primary Completion: April 2012
4 Recruiting Lower Dose Decitabine (DAC)-Primed TC (Carboplatin-Paclitaxel) Regimen in Ovary Cancer
Conditions: Primary Malignant Neoplasm of Ovary;   FIGO Stages II to IV
Interventions: Drug: Decitabine (DTC Arm);   Drug: Paclitaxel and Carboplatin (TC Arm)
Phases: Phase 2 / Phase 3
Sponsor: Chinese PLA General Hospital
Study Start: June 2014
Primary Completion: June 2024
5 Recruiting Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
Condition: Stroke
Interventions: Drug: Desmoteplase;   Drug: Placebo
Phase: Phase 3
Sponsor: H. Lundbeck A/S
Study Start: April 2009
Primary Completion: January 2015
6 Completed
Has Results
Exacerbation Study
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Indacaterol 150 µg;   Drug: Tiotropium
Phase: Phase 3
Sponsor/Collaborators: Novartis Pharmaceuticals;   Novartis
Study Start: March 2009
Primary Completion: July 2012
7 Completed
Has Results
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)
Condition: Macular Degeneration
Interventions: Drug: Ranibizumab;   Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
Phase: Phase 3
Sponsor/Collaborators: Bayer;   Regeneron Pharmaceuticals
Study Start: April 2008
Primary Completion: September 2010
8 Recruiting ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727)
Condition: Acute Coronary Syndrome
Interventions: Drug: alirocumab SAR236553 (REGN727);   Other: placebo
Phase: Phase 3
Sponsor/Collaborators: Sanofi;   Regeneron Pharmaceuticals
Study Start: October 2012
Primary Completion: January 2018

Indicates status has not been verified in more than two years